Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005946 · ClinicalTrials.gov registry record · Phase 1
Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation
A Phase 1 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00005946: Completed Phase 1 study, sponsored by University of Maryland, Baltimore.
NCT00005946 is a Phase 1 study that has completed, run by University of Maryland, Baltimore. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005946, a Phase 1 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. White blood cells from donors may be able to prevent graft-versus-host disease in patients with hematologic cancer that has relapsed following donor peripheral stem cell transplantation. PURPOSE: Phase I trial to study the effectiveness of chemotherapy plus donor white blood cell infusion in treating patients who have relapsed hematologic cancer following donor peripheral stem cell transplantation.
Interventions
- DRUG cyclophosphamide
- DRUG etoposide
- BIOLOGICAL filgrastim
- BIOLOGICAL therapeutic allogeneic lymphocytes
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-10 |
| Est. Completion | 2002-06 |
| Phase | Phase 1 |
What the finished NCT00005946 record still lists
NCT00005946 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 4 interventions - of which cyclophosphamide is the first listed.
NCT00005946 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00005946 about?
NCT00005946 is a clinical study titled "Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. White blood cells from donors may be able to prevent graft-versus-host disease in patients with hematologic cancer that has relapsed following donor peripheral stem cell transplant...
What is the current status of trial NCT00005946?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-10. Estimated completion is 2002-06.
What interventions are being tested in trial NCT00005946?
The interventions under investigation include: cyclophosphamide (DRUG), etoposide (DRUG), filgrastim (BIOLOGICAL), therapeutic allogeneic lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005946?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia